J&J Needs to End Talc Lawsuits. The Third Time Could Be the Charm. Aug. 28, 2024 2:05 p.m. ET Dow Pulls Back From Record. S&P 500 Isn't Looking Good Either. Aug. 22, 2024 5:08 p.m. ET Altria Boosts Its Dividend for the 55th Straight Year. Yield Is Now Nearly 8% Aug. 20...
Risk: Tens of thousands of plaintiffs have sued JNJ, alleging that the company’s baby powder and other talc products sometimes contained asbestos and caused ovarian cancer and mesothelioma. The company's attempt to use its subsidiary's bankruptcy to halt these lawsuits was rejected by the court...
In April, J&J's subsidiary, LTL Management, filed for bankruptcy in New Jersey, proposing to pay nearly $9 billion to settle more than 38,000 lawsuits and prevent new cases from coming forward. It's the company's second attempt to resolve talc claims in bankruptcy court after a federal ap...
As announced on May 1, the company has committed to pay ovarian claimants a present value of approximately $6.5 billion or $8 billion nominally over 25 years, resolving 99.75% of all pending talc lawsuits against the company and its affiliates in the United States. We are currently in a vo...
Johnson & Johnson proposes to pay $6.5B to settle talc ovarian cancer lawsuits in US Through a bankruptcy filing of its subsidiary company, J&J will be able to resolve about 99.75% of the pending talc lawsuits against the company and its affiliates in the U.S. ...
johnson & johnson value appraisal with the talc lawsuits jun. 28, 2019 2:20 pm et johnson & johnson (jnj) stock 116 comments 25 likes richard berger 10.78k follower s follow summary talc lawsuits raise questions of jnj dividend safety and existential fate of the company. near and long-te...
So what exactly is dragging JNJ stock down today? Concerns from the company about itslarge amount of lawsuitsis one issue. Pressure from the government about its alleged role in the opioid crisis also isn’t doing it any favors, either. ...
Then there is baby powder. There have been13,000 lawsuitsfiled against Johnson & Johnson over the last two years, charging cancer-causing asbestos has been in the product for decades. CEO Alex Gorsky was forced to testify in one such lawsuit,which the company lost. An appeal is pending. ...
Jagielski goes on to suggest that there are safer long-term dividend plays available given the lawsuits the company faces aren’t going away. Further, he reminds investors that Johnson & Johnson is no longer the kind of stock that you can stick in a drawer and forget...
Investors looking for high-growth healthcare stocks that pay a dividend will find JNJ stock to be a worthy investment. Although the company does come with risks, such as pending lawsuits, it is still in a good position when assessing the long-term potential. ...